



2010 Key figures




Growth

Organic growth continued at a fast pace in a difficult economic climate.




Operating profit margin

Operating profit margin grew by 420 basis points to 20.9%.




R&D / Sales

R&D returned to 19% of sales, marking the end of the Oralair® trial in the USA.



Workforce (end of year)

Stallergenes created 77 net positions in 2010. In 5 years, the workforce increased by 70%.



Net profit margin


Net profit margin reached a record high of 14.2% since the IPO.




■ R&D
□ Investment in equipment

Stalair® Programme

Since its launch in 2004, Stallergenes has invested € 170 million in the Stalair® programme.



Sales analysis by range



Sales analysis by market

* Spain, France, Greece, Italy and Portugal